OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i

20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs p

Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the

OS Therapies shares rise after OST-HER2 Phase 2b data showed a 75% survival rate and progress toward

75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no ne

Lake Street analyst Chad Messer maintains OS Therapies (AMEX:OSTX) with a Buy and lowers the pric

OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.27) per share which missed the analyst con

Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune

New patent application covers treatment-emergent immune signature related to 'turning cold tumor

OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.41) per share which missed the analyst con

OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i

Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with ex

FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated

OS Therapies shares climb after new regulatory plans for OST-HER2 osteosarcoma treatment in the UK,

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain

OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in

OS Therapies releases trial data supporting FDA approval, U.K. and U.S. timelines, and potential eli

Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivor

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain

OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain

FDA confirmed that data from single-arm studies in rare diseases, such as in ultra-rare deadly pedia

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain

Alignment achieved on all key points surrounding non-clinical, CMC and post-market authorization con

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain

U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2Scheduled pre-Marketing Authoris

OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain

OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in

Lake Street analyst Chad Messer maintains OS Therapies (AMEX:OSTX) with a Buy and lowers the pric

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain

OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in

OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage ca

Final FDA Type C Meeting December 11, 2025 - biomarker data to be availableOctober 10, 2025 FDA/Oste

OS Therapies reports 75% two-year survival in osteosarcoma trial, plans regulatory filings with the

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain

Overall survival recognized as key efficacy endpoint in osteosarcoma, where no standard of care exis

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain